Abstract
Our understanding of estrogen (E2) receptor biology has evolved in recent years with the discovery and characterization of a 7-transmembrane-spanning G protein-coupled estrogen receptor (GPER1/GPER/GPR30) and the development of GPER-selective functional chemical probes. GPER is highly expressed in certain breast, endometrial and ovarian cancers, establishing the importance of non-invasive methods to evaluate GPER expression in vivo.
Herein, we developed retaining a ketone functionality displayed agonist properties whereas those lacking such a hydrogen bond acceptor were antagonists. In vivo biodistribution and imaging studies performed on mice bearing human endometrial and breast cancer cell xenografts yielded significant tumor uptake (0.4-1.1 %ID/g). Blocking studies revealed specific uptake in multiple organs (adrenals, uterus, mammary tissue) as well as tumor uptake with similar levels of competition by E2 and G-1, a GPER-selective agonist. In conclusion, we synthesized and evaluated a series of first generation 99m
Introduction
Estrogen mediates profound effects throughout the body and regulates physiological and pathological processes in both women and men. The lower prevalence of many diseases in premenopausal women compared to postmenopausal women or age-matched men is widely attributed to the presence of 17β-estradiol, the predominant and most potent endogenous estrogen (1-3). 17β-Estradiol, although commonly recognized as the female sex hormone, also has critical roles in additional normal physiological processes within the nervous, immune, vascular, muscular, skeletal and endocrine systems (2, (4) (5) (6) (7) (8) . In addition, 17β-estradiol signaling plays an important role in various pathological conditions and disorders, including cancer, cardiovascular diseases, hypertension, osteoporosis, cognitive and behavioral alterations, neurodegenerative diseases, as well as metabolic and immune disorders (2, (4) (5) (6) (7) (8) . However, elucidating the exact role(s) of 17β-estradiol in these processes is often complicated by the existence of several types of estrogen receptors (ERs) and multiple modes of cellular signaling mechanisms that span time frames from seconds to hours, or even days (6, 9) . The actions of estrogen have traditionally been ascribed to one of two closely related classical nuclear hormone receptors, ER-alpha (ERα) and ER-beta (ERβ), which are best characterized for regulating gene expression (10, 11), and their membrane-localized variants. Recent studies have revealed the contribution of a novel estrogen receptor GPER (previously GPR30), which belongs to the family of seven-transmembrane G protein-coupled receptors, to many of the rapid cellular and biological metastases, regardless of ER status (27) . Additional studies have found that GPER protein is overexpressed in ovarian cancer where it is associated with lower survival rates (28, 29) .
Similarly, GPER is overexpressed in tumors where estrogen and progesterone receptors are down regulated and in high-risk endometrial cancer patients with lower survival rates (30, 31) .
GPER is also widely expressed in cancer cell lines isolated from diverse organs as well as primary tumors of the thyroid, lung, prostate, pancreas and testicular germ cells, in addition to the breast, endometrium and ovaries (6, 12, (32) (33) (34) .
Importantly, in breast cancer patients treated only with tamoxifen, GPER protein expression was increased and survival was markedly reduced in patients with initial GPERpositive tumors, suggesting that patients with breast cancer who have high GPER protein expression should not be treated exclusively with tamoxifen (35) . Cellular effects of tamoxifen via GPER were further demonstrated through tamoxifen-mediated stimulation of tumor cell proliferation and migration (36) (37) (38) . Thus, although anti-estrogens such as tamoxifen, fulvestrant and raloxifene function as ERα antagonists, they act as GPER agonists (39) (40) (41) (42) , stimulating proliferation and other cellular activities via the GPER-mediated transactivation of EGFR (43).
Several radiopharmaceuticals have been developed for the non-invasive imaging and assessment of ER status (44-48). The most successful estrogen radiopharmaceutical 16α- 
Materials and Methods

Chemical synthesis of non-steroidal GPER-specific ligands
Synthetic derivatives of the GPER-targeting tetrahydro-3H-cyclopenta[c]quinoline scaffold possessing different chelating heterocyclic aminocarboxylate ligands with demonstrated capacity for the formation of neutral tricarbonylrhenium(I) and tricarbonyltechnetium(I) complexes at the C8 position were prepared as previously described (54) . Ligand compounds containing a pyridin-2-ylhydrazinylethanoic acid group (1, 3, 4) , or pyridin-2-yl-methylaminoethanoic acid (2), were prepared as the tert-butyl esters with nitrogen groups protected as tert-butoxycarbonyl derivatives, and deprotected with trifluoroacetic acid in dichloromethane at ambient temperature before labelling. The non-radioactive tricarbonylrhenium(I) complexes (5-Re:8-Re) were prepared as previously described (54) .
Radiosynthesis of 99m
Tc(I)-labeled non-steroidal GPER-specific ligands
The organometallic aqua ion labeling agent [ 99m Tc(CO) 3 Tc (if any) and excess ligand were separated using solid phase extraction (SPE). SPE was performed using C-18 SepPak Plus cartridges (Waters, Milford, MA USA). The impurities and excess ligand were eluted with 4 x 0.5 mL fractions of the weak solvent (50% ethanol in water).
Elution of the final non-steriodal GPER-specific ethanol (JT Baker, Phillipsburg, NJ, USA). To assess radiochemical purity and specific activity, 10 µL of the diluted quality control sample was injected on a reverse-phase C-18 column (JT Baker, Phillipsburg, NJ, USA) using HPLC grade ethanol and HPLC grade water as previously described (55) . Stability, transchelation and partition coefficient studies were performed as previously described (55) . 
Cell culture and receptor binding studies
Histological staining of tumors
Sections (5 μm) from paraffin-embedded ~10-week tumors were prepared for immunohistochemistry (IHC) using an affinity purified polycolonal antibody raised against the carboxy-terminus of GPER as previously described (59) . Briefly, sections were deparaffinized in CitriSolv (Fisher, Pittsburgh, PA), followed by rehydration in increasing H 2 O:ethanol solutions.
Antigen retrieval was carried out by microwaving slides in 0.01 M sodium citrate buffer (pH 6.0) for 25 min, followed by incubation in fresh 2% H 2 O 2 for 10 min. Permeabilization and blocking were carried out by incubating the slides for 30 min in 200 µL 0.1% Triton X-100 in PBS containing 3% BSA in a humid chamber. Slides were then incubated with the GPER carboxy-terminal antibody diluted to a final protein concentration of 2 µg/mL in 3% normal goat serum for 1 h. Following washes, bound antibody was detected using goat anti-rabbit IgG conjugated to horseradish peroxidase (diluted 1:250 in 3% normal goat serum, 45 min), which was detected with 3',3-diaminobenzidine tetrahydrochloride (DAB; Sigma, St Louis, MO).
Biodistribution and SPECT/CT imaging studies
Conscious tumor-bearing mice were injected in the tail vein with selected GPER-targeted 99m Tclabeled agents. To determine receptor specificity, 5 µg GPER-selective agonist G-1 or 5 µg receptor-nonselective ligand 17β-E2 was co-injected with the radiotracer. At the desired time points, the animals were sacrificed by carbon dioxide inhalation. Tumor, blood and selected normal organs were harvested, weighed, and the radioactivity measured in a Wallace Wizard 1480 gamma counter (PerkinElmer, Shelton, CT). The percentage of the injected dose per gram of tissue (% ID/g) was calculated by comparison with standards representing 10% of the injected dose per animal. High-resolution in vivo SPECT/CT imaging studies were performed using a multi-pinhole NanoSPECT/CT small animal imager (Bioscan Inc, Washington DC, USA) with whole body and focused imaging studies carried out on anesthetized mice (1.5-1.7% isoflurane) 9 on a temperature-controlled bed (36-38 ºC). Images were co-registered and analyzed using InVivoScope software program (Bioscan Inc, Washington DC, USA).
Statistical Analysis
All numerical data were expressed as the mean of the values ± the standard error of mean (S.E.M). GraphPad Prism version 5 (San Diego, CA, USA) was used for statistical analysis and analysis of competitive binding data, which was performed using a single fit model. A P value ≤ 0.05 was considered statistically significant. with increased specific activity, HPLC analysis revealed the presence of trace degradation products and the radiochemical purity was less than 70% under these conditions. The higher radiolabeling yields and increased purity obtained using the room temperature procedure were advantageous for the subsequent in vivo studies.
Results
Radiochemistry
Stability, transchelation and partition coefficient studies
All of the Table 3 for summary).
Biodistribution in tumor-bearing animals
Biodistribution studies were performed in ovariectomized athymic (NCr) nu/nu female mice bearing Hec50 and MCF7/HER2-18 cell tumor xenografts by injecting 1.5 MBq (Table S1 ).
All of the evaluated 99m
Tc-labeled derivatives demonstrated receptor specificity when GPER blocking studies were performed by co-injecting 5 µg G-1 with the corresponding radiotracer (Fig. 3) . GPER-mediated uptake was observed in the adrenals, uterus, mammary tissue and the Hec50 and MCF7/HER2-18 tumors (Fig. 3 and Table 2 ). Of the Tc was found in the urine. The remaining radioactive species were hydrophilic radiometabolites (Fig. S2A) . At 2 h PI, 5-99m Tc was completely metabolized (Fig.   S2B) . At 4 h PI, most of the radiometabolites were excreted and the only radioactive species circulating in the blood on HPLC analysis of the plasma sample was the injected radiotracer (Fig.   S2C) . Similarly, for 6-99m Tc, at 2 h PI most of the radioactive species were hydrophilic radiometabolites. The excretion of the three radiotracers ranged from 8-14% ID at 3 h PI.
A detailed in vivo study of GPER ligand specificity was performed using 5- Tc agent exhibited specific binding to target organs at 1, 2 and 3 h PI, suggesting limited non-specific uptake of a radiometabolite in the target organs (Fig. 3D) . Furthermore, at 3 h PI, the level of inhibition of 5-99m Tc uptake was similar when either G-1 or E2 was co-injected, demonstrating 5- 
up to 6 h PI (1.10 ± 0.27% ID at 3 h PI vs. 1.23 ± 0.16% ID at 6 h PI). Over 70% ID was in the liver, gall bladder and the intestines at 3 and 6 h PI. 
Discussion
Roles for the membrane-bound G protein-coupled estrogen receptor GPER in resistance to endocrine therapy and aggressive forms of breast, ovarian and endometrial carcinoma have been reported (6, (59) (60) (61) (62) (63) . The GPER-selective ligands G-1, G15 and G36 have been extensively used (with >120 publications) to elucidate the roles and functions of this receptor in normal physiology and pathology (6, 37, 39, 52). Although consensus supports the involvement of GPER in many estrogenic responses, a small number of conflicting reports have suggested that GPER may not function as an estrogen receptor in vitro or in vivo (24, 26, 64) . To further address the functions of GPER in vivo, we developed radiolabeled GPER-specific agents and performed in vivo competition binding studies using radiotracer principles to demonstrate the expression profile of GPER in various tissues and in different ERα/β-and/or GPER-expressing tumor xenograft cancer models. We also evaluated whether these radiolabeled GPER-specific agents can be used for non-invasive GPER visualization of tumors.
Based on our previous studies, we had demonstrated the need for an uncharged neutral agent for intracellular targeting of GPER (65, 66); therefore we synthesized a series of uncharged neutral GPER-selective agents based on organometallic rhenium(I)/technetium(I) tricarbonyl chemistry (54). Radioligand receptor-binding studies revealed binding affinities in the 10-30 nM range, demonstrating minimal to moderate loss of affinity relative to the parent molecules G-1 and G15. Cellular signaling assays previously demonstrated that derivatives retaining a hydrogen bond acceptor ketone functionality in the linker displayed agonist properties whereas those lacking this moiety were antagonists (54) . In vivo biodistribution studies revealed further differences associated with the structures of the linkages; the radiolabeled conjugate 7- 
